•  
  •  
 

Abstract

Sickle cell disease (SCD) is a hereditary ailment that can cause severe pain and suffering to people who are affected. However, with continued investment in research and treatment options, we can make progress towards improving the lives of those with SCD. Over 40% of patients experience painful vaso-occlusive crises (VOCs), so we must work towards finding solutions and providing support for those living with this condition, These episodes, a hallmark of SCD, significantly contribute to morbidity, mortality, and a diminished quality of life, while also incurring substantial healthcare costs. Chronic pain particularly affects older adolescents and adults with SCD, with over half reporting daily discomfort. Opioid-based analgesics, though still the main form of pain management, have limitations. Their effectiveness is limited, and they come with risks of adverse effects and addiction. Therefore, exploring alternative, for pain management strategies is crucial. This review dives into the potential of pharmacological supplements for this purpose. Deficiency in vitamin D is linked to increased complications in SCD. While evidence suggests vitamin D supplementation might help manage pain in SCD patients, more clinical trials are needed to confirm this benefit and determine the most effective dosage. L-arginine supplementation shows promise in reducing pain and hospital stays, while inhaled nitric oxide has yielded mixed results. Zinc deficiency is common in SCD, and supplementation may decrease infections, improve immunity, and reduce pain crises. Because of their anti-inflammatory qualities, omega-3 fatty acids may lessen the frequency of pain and inflammatory markers. Overall, the evidence for most supplements remains inconclusive, highlighting the need for further clinical research for promising supplements of vitamin D and omega-3, to establish definitive conclusions regarding their efficacy and safety in SCD patients. Exploring combination therapies and tailoring interventions to individual needs may hold promise for comprehensive pain management strategies.

References

References

[1] Sickle Cell Disease. WHO, Regional Office for Africa. Available from: https://www.afro.who.int/health-topics/ sickle-cell-disease.

[2] Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet Lond Engl 2013;381(9861): 142-51.

[3] K Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene- Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Prim 2018;4:18010.

[4] Zaidi AU, Glaros AK, Lee S, Wang T, Bhojwani R, Morris E, et al. A systematic literature review of frequency of vasoocclusive crises in sickle cell disease. Orphanet J Rare Dis 2021;16(1):460. https://doi.org/10.1186/s13023-021-02096-6.

[5] Sil S, Cohen LL, Dampier C. Psychosocial and functional outcomes in youth with chronic sickle cell pain. Clin J Pain 2016;32(6):527-33.

[6] Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine 2005;84(6):363-76.

[7] Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008;148(2): 94-101.

[8] Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009;84(6):323-7.

[9] Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 2005 May;78(1):9-13.

[10] Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol 2008;16(5):405-16.

[11] Sinha CB, Bakshi N, Ross D, Krishnamurti L. Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: a qualitative study. JAMA Netw Open 2019;2(5):e194410. https://doi.org/10.1001/jamanetworkopen. 2019.4410.

[12] Brandow AM, Carroll CP, Creary S, Edwards-Elliott R, Glassberg J, Hurley R, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv 2020;4(12):2656-701.

[13] AlJama A, AlKhalifah M, Al-Dabbous IA, Alqudaihi G. Vitamin D deficiency in sickle cell disease patients in the Eastern Province of Saudi Arabia. Ann Saudi Med 2018;38(2): 130-6.

[14] Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25- hydroxyvitamin D. J Am Coll Nutr 2003;22:142-6.

[15] Hamdy M, Salama N, Elrefaee A, Maher G. Vitamin D deficiency in Egyptian children with sickle cell disease: prevalence and clinical implications. Adv Hematol 2018;2018: PMC6164208.

[16] Jackson TC, Krauss MJ, Debaun MR, Strunk RC, Arbel_aez AM. Vitamin D deficiency and comorbidities in children with sickle cell anemia. Pediatr Hematol Oncol 2012;29(3):261-6.

[17] Lee MT, Licursi M, McMahon DJ. Vitamin D deficiency and acute vaso-occlusive complications in children with sickle cell disease. Pediatr Blood Cancer 2015;62(4):643-7.

[18] Hood AM, Quinn CT, King CD, Shook LM, Peugh JL, Crosby LE. Vitamin D supplementation and emergency department visits in pediatric patients with sickle cell disease. Pediatr Blood Cancer 2021 Mar;68(3):e28733.

[19] Adegoke SA, Smith OS, Adekile AD, Figueiredo MS. Relationship between serum 25-hydroxyvitamin D and inflammatory cytokines in paediatric sickle cell disease. Cytokine 2017;96:87-93.

[20] Abdelhalim SM, Murphy JE, Meabed MH, Elberry AA, Gamaleldin MM, Shaalan MS, et al. Comparative effectiveness of adding Omega-3 or Vitamin D to standard therapy in preventing and treating episodes of painful crisis in pediatric sickle cell patients. Eur Rev Med Pharmacol Sci 2022;26(14): 5043-52.

[21] Osunkwo I, Ziegler TR, Alvarez J, et al. High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study. Br J Haematol 2012;159(2):211-5.

[22] Lee MT, Kattan M, Fennoy I, Arpadi SM, Miller RL, Cremers S, et al. Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. Blood Adv 2018;2(9):969-78.

[23] Gr_egoire-Pelchat P, Pastore Y, Robitaille N, LeMay S, Khamessan A, Kleiber N, et al. Comparison of two vitamin D supplementation strategies in children with sickle cell disease: a randomized controlled trial. Br J Haematol 2021 Jan; 192(2):385-94.

[24] Morris SM. Regulation of arginine availability and its impact on NO synthesis. In: Ignarro LJ, editor. Nitric oxide. Academic Press; 2000. p. 187-97.

[25] Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000;22(6):515-20.

[26] Morris CR, Brown LAS, Reynolds M, Dampier CD, Lane PA, Watt A, et al. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vasoocclusive pain. Blood 2020;136(12):1402-6.

[27] Bakshi N, Morris CR. The role of the arginine metabolome in pain: implications for sickle cell disease. J Pain Res 2016;9(1): 167-75.

[28] Saramba MI, Shakya S, Zhao D. Analgesic management of uncomplicated acute sickle-cell pain crisis in pediatrics: a systematic review and meta-analysis. Journal de Pediatria 2020;96(2):142-58.

[29] Onalo R, Cooper P, Cilliers A, Vorster BC, Uche NA, Oluseyi OO, et al. Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. Am J Hematol 2021;96(1):89-97.

[30] Morris CR, Kuypers FA, Lavrisha L, Ansari M, Sweeters N, Stewart M, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica Internet] 2013 May 3 cited 2019 Nov 9];98(9): 1375-82.

[31] Eleut_erio RMN, Nascimento FO, Araújo TG, Castro MF, Filho TPA, Filho PAM, et al. Double-blind clinical trial of arginine supplementation in the treatment of adult patients with sickle cell anaemia. Advances in Hematology 2019 Feb 3;2019:1-6.

[32] Reyes LZ, Figueroa J, Leake D, Khemani K, Kumari P, Bakshi N, et al. Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vasoocclusive pain: a randomized placebo-controlled trial in progress. Am J Hematol 2021 Nov 12;97(1).

[33] Gladwin MT. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis. JAMA 2011 Mar 2;305(9):893.

[34] Alvin Head C, Swerdlow P, McDade WA, Ratan Mani Joshi, Ikuta T, Cooper MM, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol 2010 Oct 1;85(10):800-2.

[35] Weiner DL. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2003 Mar 5;289(9):1136.

[36] Phebus CK, Maciak BJ, Gloninger MF, Paul HS. Zinc status of children with sickle cell disease: relationship to poor growth. Am J Hematol Internet] 1988 Oct 1;29(2):67-73 cited 2021 Aug 20].

[37] Prasad AS, Beck FW, Kaplan J, Chandrasekar PH, Ortega J, Fitzgerald JT, et al. Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD). Am J Hematol 1999 Jul 1;61(3): 194-202.

[38] Khan SA, Damanhouri GA, Ahmed TJ, Halawani SH, Ali A, Makki A, et al. Omega 3 fatty acids - potential modulators for oxidative stress and inflammation in the management of sickle cell disease. J Pediatr 2022 Feb;98(5):513-8.

[39] Setty BNY, Betal SG, Miller RE, Brown DS, Meier M, Cahill M, et al. Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia. Prostagl Leukot Essent Fat Acids 2019 Jul;146:11-8.

[40] Okpala I, Ibegbulam O, Duru A, Ocheni S, Emodi I, Ikefuna A, et al. Pilot study of omega-3 fatty acid supplements in sickle cell disease. APMIS 2011 Apr 17;119(7):442-8.

[41] bdelhalima SM, Murphy JE, Meabed MH, Elberry AA, Gamaleldin MM, Alshaeri HK, et al. Cost-effectiveness analysis of adding omega-3 or vitamin D supplementation to standard therapy in treating painful crises of pediatric sickle cell disease patients. Eur Rev Med Pharmacol Sci 2022 Oct 1; 26(20):7506-13.

[42] Daak AA, Ghebremeskel K, Hassan Z, Attallah B, Azan HH, Elbashir MI, et al. Effect of omega-3 (n_3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2012 Nov 28;97(1):37-44.

[43] Tomer A, Kasey S, Connor W, Clark S, Harker L, Eckman J. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. Thromb Haemostasis 2001;85(6):966-74.

Download

Share

COinS